Revenue plus France: Preparing for Buy-Out
While swimming under $1 pps, the shorts sold Amarin at their own profit into the abyss. But that's not where it will end as French approval will be a literal game-changer. I've seen it before especially in spec-biotechs. That price is held down until that one single piece of news follows low-voiced phone calls among HFs tipping the company's about to be sold, or a major deal is about to be announced. Meanwhile, the runway higher is paved with riches, and when it's all over, you'll be genius for having loaded up shares.
Bullish
Market Data 
Markets 
AI
